Adrenal incidentalomas and cardiometabolic morbidity: An emerging association with serious clinical implications

Journal of Internal Medicine

Volumn 268, Issue 6, 2010, Pages 555-566

  Peppa, M ^a   Koliaki, C ^a   Raptis, S A ^b,c  

^a Endocrine Unit   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Hellenic National Diabetes Center   (Greece)

Author keywords

Adrenal incidentalomas; Insulin resistance; Metabolic syndrome; Nonfunctioning adrenal incidentalomas; Subclinical Cushing's syndrome

Indexed keywords

ALDOSTERONE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CORTICOTROPIN; D DIMER; DEXAMETHASONE; HYDROCORTISONE; INSULIN; INTERLEUKIN 6; RENIN; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ADRENAL GLAND; ADRENAL TUMOR; ADRENALECTOMY; ALGORITHM; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CORTICOTROPIN BLOOD LEVEL; CUSHING SYNDROME; CYTOKINE RELEASE; DEXAMETHASONE SUPPRESSION TEST; DISEASE ASSOCIATION; DISEASE COURSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; IMPAIRED GLUCOSE TOLERANCE; INCIDENTALOMA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LABORATORY TEST; LOW DRUG DOSE; METABOLIC REGULATION; METABOLIC SYNDROME X; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TREATMENT OUTCOME; TUMOR DIAGNOSIS; WEIGHT REDUCTION;

ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; CUSHING SYNDROME; HUMANS; HYDROCORTISONE; INCIDENTAL FINDINGS; METABOLIC SYNDROME X;

EID: 78649455481     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02291.x     Document Type: Review

References (49)

1. Young Jr WF. Clinical practice. The incidentally discovered adrenal mass. New Engl J Med 2007; 356: 601-10.
2. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004; 25: 309-40.
3. Linos DA, Stylopoulos N, Raptis SA. Adrenaloma: a call for more aggressive management. World J Surg 1996; 20: 788-92. discussion 792-3.
4. Singh PK, Buch HN. Adrenal incidentaloma: evaluation and management. J Clin Pathol 2008; 61: 1168-73.
5. Terzolo M, Pia A, Alì A et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 2002; 87: 998-1003.
6. Zhang W, Tang ZY, Wang WQ, Ning G. Metabolic syndrome in patients with adrenocortical adenoma. Zhonghua Yi Xue Za Zhi 2006; 86: 3397-400.
7. Peppa M, Koliaki C, Nikolopoulos P, Raptis SA. Skeletal muscle insulin resistance in endocrine disease. J Biomed Biotechnol 2010; 2010: 527850.
8. Reincke M, Fassnacht M, Väth S, Mora P, Allolio B. Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr Res 1996; 22: 757-61.
9. Kandaraki E, Christakou C, Diamanti-Kandarakis E. Metabolic syndrome and polycystic ovary syndrome and vice versa. Arq Bras Endocrinol Metabol 2009; 53: 227-37.
10. Giordano R, Marinazzo E, Berardelli R et al. Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur J Endocrinol 2010; 162: 779-85.
11. Vassilatou E, Vryonidou A, Michalopoulou S et al. Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study. Clin Endocrinol (Oxf) 2009; 70: 674-9.
12. Yener S, Ertilav S, Secil M et al. Prospective evaluation of tumor size and hormonal status in adrenal incidentalomas. J Endocrinol Invest 2010; 33: 32-6.
13. Peppa M, Boutati E, Koliaki C et al. Insulin resistance and metabolic syndrome in patients with non-functioning adrenal incidentalomas: a cause-effect relationship? Metabolism 2010; 59: 1435-41.
14. Bernini G, Moretti A, Iacconi P et al. Anthropometric, haemodynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur J Endocrinol 2003; 148: 213-9.
15. Fernández-Real JM, Engel WR, Simó R, Salinas I, Webb SM. Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Study Group of Incidental Adrenal Adenoma. Clin Endocrinol (Oxf) 1998; 49: 53-61.
16. Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T. The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf) 2001; 54: 797-804.
17. Wagnerova H, Dudasova D, Lazurova I. Hormonal and metabolic evaluation of adrenal incidentalomas. Neoplasma 2009; 56: 521-5.
18. Yilmaz H, Tütüncü NB, Sahin M. Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas. J Endocrinol Invest 2009; 32: 913-6.
19. Comlekci A, Yener S, Ertilav S et al. Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience. Endocrine 2009 (Epub ahead of print).
20. Ivovií M, Vujovií S, Penezií Z, Zarkovií M, Drezgií M. Insulin sensitivity in patients with adrenal incidentaloma. Srp Arh Celok Lek 2006; 134: 315-9.
21. Yener S, Genc S, Akinci B et al. Carotid intima media thickness is increased and associated with morning cortisol in subjects with non-functioning adrenal incidentaloma. Endocrine 2009; 35: 365-70.
22. Yener S, Comlekci A, Akinci B et al. Non-functioning adrenal incidentalomas are associated with elevated D-dimer levels. J Endocrinol Invest 2009; 32: 338-43.
23. Yener S, Baris M, Secil M, Akinci B, Comlekci A, Yesil S. Is there an association between non-functioning adrenal adenoma and endothelial dysfunction? J Endocrinol Invest 2010 (Epub ahead of print).
24. Rossi R, Tauchmanova L, Luciano A et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 2000; 85: 1440-8.
25. Sereg M, Szappanos A, Toke J et al. Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study. Eur J Endocrinol 2009; 160: 647-55.
26. Izaki H, Fukumori T, Takahashi M et al. Indications for laparoscopic adrenalectomy for non-functional adrenal tumor with hypertension: usefulness of adrenocortical scintigraphy. Int J Urol 2006; 13: 677-81.
27. Piaditis GP, Kaltsas GA, Androulakis II et al. High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clin Endocrinol (Oxf) 2009; 71: 772-8.
28. Seppel T, Schlaghecke R. Augmented 17 alpha-hydroxyprogesterone response to ACTH stimulation as evidence of decreased 21-hydroxylase activity in patients with incidentally discovered adrenal tumours ('incidentalomas'). Clin Endocrinol (Oxf) 1994; 41: 445-51.
29. Dall'Asta C, Barbetta L, Libé R, Passini E, Ambrosi B. Coexistence of 21-hydroxylase and 11 beta-hydroxylase deficiency in adrenal incidentalomas and in subclinical Cushing's syndrome. Horm Res 2002; 57: 192-6.
30. Del Monte P, Bernasconi D, Bertolazzi L et al. Increased 17 alpha-hydroxyprogesterone response to ACTH in silent adrenal adenoma: cause or effect? Clin Endocrinol (Oxf) 1995; 42: 273-7.
31. Sippel RS, Chen H. Subclinical Cushing's syndrome in adrenal incidentalomas. Surg Clin North Am 2004; 84: 875-85.
32. Maser-Gluth C, Reincke M, Allolio B, Schulze E. Metabolism of glucocorticoids and mineralocorticoids in patients with adrenal incidentalomas. Eur J Clin Invest 2000; 30(Suppl 3): 83-6.
33. Kotłowska A, Maliński E, Sworczak K, Kumirska J, Stepnowski P. The urinary steroid profile in patients diagnosed with adrenal incidentaloma. Clin Biochem 2009; 42: 448-54.
34. Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T, Sasano H. Analysis of cortisol secretion in hormonally inactive adrenocortical incidentalomas: study of in vitro steroid secretion and immunohistochemical localization of steroidogenic enzymes. Endocr J 2001; 48: 167-74.
35. Beuschlein F, Borgemeister M, Schirra J et al. Oral glucose tolerance testing but not intravenous glucose administration uncovers hyper-responsiveness of hypothalamo-pituitary-adrenal axis in patients with adrenal incidentalomas. Clin Endocrinol (Oxf) 2000; 52: 617-23.
36. Ermetici F, Malavazos AE, Corbetta S et al. Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. Metabolism 2007; 56: 686-92.
37. Judd AM, Call GB, Barney M et al. Possible function of IL-6 and TNF as intraadrenal factors in the regulation of adrenal steroid secretion. Ann N Y Acad Sci 2000; 917: 628-37.
38. Harman E, Karadeniz M, Biray C et al. The relation of adiponectin and tumor necrosis factor alpha levels between endothelial nitric oxide synthase, angiotensin-converting enzyme, transforming growth factor beta and tumor necrosis factor alpha gene polymorphism in adrenal incidentalomas. J Endocrinol Invest 2009; 32: 881-8.
39. Mantero F, Terzolo M, Arnaldi G et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85: 637-44.
40. Gagliardi L, Torpy DJ. Subclinical Cushing's syndrome in adrenal incidentaloma: a common problem or an artefact of current diagnostic testing? Clin Endocrinol (Oxf) 2010; 72: 277-8.
41. Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J Endocrinol Invest 2006; 29: 471-82.
42. Tauchmanovà L, Rossi R, Biondi B et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002; 87: 4872-8.
43. Emral R, Uysal AR, Asik M et al. Prevalence of subclinical Cushing's syndrome in 70 patients with adrenal incidentaloma: clinical, biochemical and surgical outcomes. Endocr J 2003; 50: 399-408.
44. Erbil Y, Ademoǧlu E, Ozbey N et al. Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J Surg 2006; 30: 1665-71.
45. Morelli V, Masserini B, Salcuni AS et al. Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf) 2010; 73: 161-6.
46. Mauclère-Denost S, Duron-Martinaud S, Nunes ML et al. Surgical excision of subclinical cortisol secreting incidentalomas: impact on blood pressure, BMI and glucose metabolism. Ann Endocrinol (Paris) 2009; 70: 211-7.
47. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg 2009; 249: 388-91.
48. Chiodini I, Morelli V, Salcuni AS et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 2010; 95: 2736-45.
49. Nestler JE, McClanahan MA. Diabetes and adrenal disease. Baillieres Clin Endocrinol Metab 1992; 6: 829-47.